The stock of Gyre Therapeutics Inc (GYRE) has gone up by 1.01% for the week, with a -40.36% drop in the past month and a -27.02% drop in the past quarter. The volatility ratio for the week is 11.28%, and the volatility levels for the past 30 days are 10.97% for GYRE. The simple moving average for the past 20 days is -15.57% for GYRE’s stock, with a -27.67% simple moving average for the past 200 days.
Is It Worth Investing in Gyre Therapeutics Inc (NASDAQ: GYRE) Right Now?
The 36-month beta value for GYRE is at 1.93. Analysts have varying views on the stock, with 1 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for GYRE is 21.71M, and currently, shorts hold a 2.53% of that float. The average trading volume for GYRE on December 12, 2024 was 72.81K shares.
GYRE) stock’s latest price update
The stock price of Gyre Therapeutics Inc (NASDAQ: GYRE) has dropped by -8.83 compared to previous close of 10.99. Despite this, the company has seen a gain of 1.01% in its stock price over the last five trading days. globenewswire.com reported 2024-11-13 that Last patient completed pivotal Phase 3 trial in CHB-associated liver fibrosis in the PRC with data expected in Q1 2025 On track to initiate U.S. Phase 2 trial of F351 in MASH-associated liver fibrosis in 2025 Commercial launch of avatrombopag maleate tablets expected by the first half of 2025 Commercial launch of nintedanib expected in 2025 Cash and cash equivalents totaled $15.9 million as of September 30, 2024 SAN DIEGO, Nov. 13, 2024 (GLOBE NEWSWIRE) — Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), a self-sustainable, commercial-stage biotechnology company with clinical development programs focusing on a variety of chronic organ diseases, today announced financial results for the third quarter and nine months ended September 30, 2024, and provided a business update. “Our team has made great progress over the last several months and recently achieved a significant milestone with the final patient completing 52 weeks of study in our pivotal Phase 3 trial for F351 in CHB-associated liver fibrosis.
Analysts’ Opinion of GYRE
Many brokerage firms have already submitted their reports for GYRE stocks, with Stephens repeating the rating for GYRE by listing it as a “Overweight.” The predicted price for GYRE in the upcoming period, according to Stephens is $19 based on the research report published on April 29, 2021 of the previous year 2021.
Piper Sandler, on the other hand, stated in their research note that they expect to see GYRE reach a price target of $15. The rating they have provided for GYRE stocks is “Overweight” according to the report published on February 10th, 2021.
Raymond James gave a rating of “Outperform” to GYRE, setting the target price at $20 in the report published on May 21st of the previous year.
GYRE Trading at -24.05% from the 50-Day Moving Average
After a stumble in the market that brought GYRE to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -67.04% of loss for the given period.
Volatility was left at 10.97%, however, over the last 30 days, the volatility rate increased by 11.28%, as shares sank -37.41% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -18.34% lower at present.
During the last 5 trading sessions, GYRE rose by +1.01%, which changed the moving average for the period of 200-days by -55.90% in comparison to the 20-day moving average, which settled at $11.87. In addition, Gyre Therapeutics Inc saw -61.00% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at GYRE starting from USMAN NASSIM, who sale 3,452 shares at the price of $12.00 back on Jun 28 ’24. After this action, USMAN NASSIM now owns 1,636 shares of Gyre Therapeutics Inc, valued at $41,438 using the latest closing price.
USMAN NASSIM, the Director of Gyre Therapeutics Inc, sale 20,000 shares at $14.13 during a trade that took place back on May 01 ’24, which means that USMAN NASSIM is holding 1,636 shares at $282,577 based on the most recent closing price.
Stock Fundamentals for GYRE
Current profitability levels for the company are sitting at:
- 0.17 for the present operating margin
- 0.96 for the gross margin
The net margin for Gyre Therapeutics Inc stands at -0.33. The total capital return value is set at 0.16. Equity return is now at value -269.01, with -215.90 for asset returns.
Currently, EBITDA for the company is 20.33 million with net debt to EBITDA at -0.75. When we switch over and look at the enterprise to sales, we see a ratio of 7.84. The receivables turnover for the company is 5.19for trailing twelve months and the total asset turnover is 0.86. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.72.
Conclusion
In conclusion, Gyre Therapeutics Inc (GYRE) has had a bad performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
